Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

304 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group.
Iriyama N, Iwanaga E, Kimura Y, Watanabe N, Ishikawa M, Nakayama H, Sato E, Tabayashi T, Mitsumori T, Takaku T, Nakazato T, Tokuhira M, Fujita H, Ando M, Hatta Y, Kawaguchi T. Iriyama N, et al. Among authors: hatta y. Int J Hematol. 2024 Apr 8. doi: 10.1007/s12185-024-03758-4. Online ahead of print. Int J Hematol. 2024. PMID: 38587692
Management and Risk Factors for Pleural Effusion in Japanese Patients with Chronic Myeloid Leukemia Treated with First-line Dasatinib in Real-world Clinical Practice.
Tsuchiya S, Takaku T, Watanabe N, Iriyama N, Kimura Y, Iwanaga E, Sugimoto KJ, Mitsumori T, Ishikawa M, Nakazato T, Fujita H, Sato E, Hatta Y, Asou N, Kizaki M, Tokuhira M, Ando M, Kawaguchi T. Tsuchiya S, et al. Among authors: hatta y. Intern Med. 2023 Nov 15;62(22):3299-3303. doi: 10.2169/internalmedicine.1611-23. Epub 2023 Mar 31. Intern Med. 2023. PMID: 37005261 Free PMC article.
Clinical management of second-generation tyrosine kinase inhibitor therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase, focusing on age and dose effects.
Tokuhira M, Kimura Y, Tabayashi T, Watanabe N, Tsuchiya S, Takaku T, Iriyama N, Sato E, Nakazato T, Mitsumori T, Ishikawa M, Fujita H, Kizaki M, Ando M, Hatta Y, Iwanaga E, Kawaguchi T. Tokuhira M, et al. Among authors: hatta y. Int J Hematol. 2023 Aug;118(2):210-220. doi: 10.1007/s12185-023-03606-x. Epub 2023 May 2. Int J Hematol. 2023. PMID: 37129800
Importance of TKI treatment duration in treatment-free remission of chronic myeloid leukemia: results of the D-FREE study.
Yoshida C, Yamaguchi H, Doki N, Murai K, Iino M, Hatta Y, Onizuka M, Yokose N, Fujimaki K, Hagihara M, Oshikawa G, Murayama K, Kumagai T, Kimura S, Najima Y, Iriyama N, Tsutsumi I, Oba K, Kojima H, Sakamaki H, Inokuchi K; Kanto CML Study Group. Yoshida C, et al. Among authors: hatta y. Int J Hematol. 2023 May;117(5):694-705. doi: 10.1007/s12185-023-03549-3. Epub 2023 Feb 4. Int J Hematol. 2023. PMID: 36739328 Free PMC article. Clinical Trial.
Impact of standard-dose dipeptidyl peptidase-4 inhibitors on the incidence of graft-versus-host disease after allogeneic hematopoietic cell transplantation.
Kimura SI, Shimizu H, Miyazaki T, Sakurai M, Tanoue S, Kayamori K, Ohwada C, Yoshimura K, Nakasone H, Ohashi T, Shono K, Tachibana T, Hatano K, Okada K, Kimura Y, Seo S, Doki N, Tanaka M, Hatta Y, Takahashi S, Kanda Y; Kanto Study Group for Cell Therapy. Kimura SI, et al. Among authors: hatta y. Bone Marrow Transplant. 2023 Apr;58(4):452-455. doi: 10.1038/s41409-022-01901-5. Epub 2022 Dec 26. Bone Marrow Transplant. 2023. PMID: 36572728 No abstract available.
Macrophage depletion using clodronate liposomes reveals latent dysfunction of the hematopoietic microenvironment associated with persistently imbalanced M1/M2 macrophage polarization in a mouse model of hemophagocytic lymphohistiocytosis.
Koike T, Miura K, Hatta Y, Nakamura H, Hirabayashi Y, Yuda M, Harada T, Hirai S, Tsuboi I, Aizawa S. Koike T, et al. Among authors: hatta y. Ann Hematol. 2023 Dec;102(12):3311-3323. doi: 10.1007/s00277-023-05425-w. Epub 2023 Sep 1. Ann Hematol. 2023. PMID: 37656190
Nelarabine, intensive L-asparaginase, and protracted intrathecal therapy for newly diagnosed T-cell acute lymphoblastic leukaemia in children and young adults (ALL-T11): a nationwide, multicenter, phase 2 trial including randomisation in the very high-risk group.
Sato A, Hatta Y, Imai C, Oshima K, Okamoto Y, Deguchi T, Hashii Y, Fukushima T, Hori T, Kiyokawa N, Kato M, Saito S, Anami K, Sakamoto T, Kosaka Y, Suenobu S, Imamura T, Kada A, Saito AM, Manabe A, Kiyoi H, Matsumura I, Koh K, Watanabe A, Miyazaki Y, Horibe K. Sato A, et al. Among authors: hatta y. Lancet Haematol. 2023 Jun;10(6):e419-e432. doi: 10.1016/S2352-3026(23)00072-8. Epub 2023 May 8. Lancet Haematol. 2023. PMID: 37167992 Clinical Trial.
Pulmonary Veno-Occlusive Disease after Autologous Stem Cell Transplantation.
Hamada T, Takahashi H, Nakagawa M, Nukariya H, Ito S, Endo T, Kurihara K, Koike T, Iizuka K, Ohtake S, Ichinohe T, Maebayashi T, Miura K, Hatta Y, Nakamura H. Hamada T, et al. Among authors: hatta y. Case Rep Oncol. 2023 May 22;16(1):338-346. doi: 10.1159/000530265. eCollection 2023 Jan-Dec. Case Rep Oncol. 2023. PMID: 37384208 Free PMC article.
Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: A phase 3, placebo-controlled, double-blind, parallel-group study.
Kuwana M, Ito T, Kowata S, Hatta Y, Fujimaki K, Naito K, Kurahashi S, Kagoo T, Tanimoto K, Saotome S, Tomiyama Y; R788-1301 Investigators. Kuwana M, et al. Among authors: hatta y. Br J Haematol. 2023 Mar;200(6):802-811. doi: 10.1111/bjh.18582. Epub 2022 Dec 5. Br J Haematol. 2023. PMID: 36470677 Clinical Trial.
304 results